Keywords: Impax Labs, GlaxoSmithKline, Jalyn, Avodart, Albemarle, API prices, Patent challenge, Benign prostatic hyperplasia

Impax confirms patent challenge to GlaxoSmithKline’s Jalyn; Albemarle hikes API prices

Article | 14 September 2011

Print This

US generic drugmaker Impax Laboratories (Nasdaq: IPXL) confirms that it has initiated a challenge of the patents listed in connection ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in